Vaxcyte, Inc. — Form 10-Q
Filed November 4, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Vaxcyte amended its change-in-control/severance agreement with Mikhail Eydelman (SVP, General Counsel) effective August 31, 2026 through May 31, 2027. The amendment protects him against recent organizational changes (new Chief Legal Officer hire, reporting changes, duty modifications) by guaranteeing title, $524,000 base salary, 45% bonus, equity vesting, and garden-leave option. If terminated for cause during the protected period, he receives 9 months salary plus bonus pro-rata plus 9 months COBRA. Good Reason resignation rights are preserved through May 31, 2027, after which Good Reason resets to narrow grounds (35-mile relocation, >10% pay cut, title reduction, illegal conduct, material breach).
Why this rating
Executive retention/severance agreement with single officer; modest cash exposure (~$5.8M–$8M over 9 months including salary, bonus, benefits) represents <0.2% of $3.7B market cap; routine organizational backstop, not material to business trajectory.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.